The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# FORM D

#### OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity			
CIK (Filer ID Number)	Previous	None	Entity Type
	Names		<u> </u>
0001133869	SMI PRODUC' INC	TS	X Corporation
Name of Issuer	SMI Products, 1	Inc	Limited Partnership
Nile Therapeutics, Inc.		me.	Limited Liability Company
Jurisdiction of Incorporation/Organ DELAWARE	ization		General Partnership
Year of Incorporation/Organization			
X Over Five Years Ago			☐ Business Trust
			Other (Specify)
Within Last Five Years (Specify	Year)		
Yet to Be Formed			
2. Principal Place of Business ar	d Contact Information		
Name of Issuer			
Nile Therapeutics, Inc.			
Street Address 1		Street Address 2	
4 West 4th Ave		Suite 400	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
San Mateo	CALIFORNIA	94402	650-458-2670
3. Related Persons			
Last Name	First Name		Middle Name
Kazam	Joshua		A
Street Address 1	Street Address 2		
4 West 4th Ave	Suite 400		
City	State/Province/Cou	ntry	ZIP/PostalCode
San Mateo	CALIFORNIA		94402
Relationship: X Executive Officer	X Director Promoter		
Clarification of Response (if Neces	sary):		
Last Name	First Name		Middle Name
Evans	Daron		
Street Address 1	Street Address 2		
4 West 4th Ave	Suite 400		
City	State/Province/Cou	ntry	ZIP/PostalCode
San Mateo	CALIFORNIA		94402
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Neces	sary):		
Last Name	First Name		Middle Name
Lieu	Hsiao		D.
Street Address 1	Street Address 2		
4 West 4th Ave	Suite 400		
City	State/Province/Cou	ntry	ZIP/PostalCode
San Mateo	CALIFORNIA		94402
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Neces	sary):		

Last Name	First Name	Middle Name
Brewer	Richard	B.
Street Address 1	Street Address 2	<i>D.</i>
4 West 4th Ave	Suite 400	
City	State/Province/Country	ZIP/PostalCode
San Mateo	CALIFORNIA	94402
Relationship: X Executive Officer X Director	Promoter	74102
Clarification of Response (if Necessary):	Tromoter	
Ciamication of Response (if Necessary).		
Last Name	First Name	Middle Name
Belldegrun	Arie	S.
Street Address 1	Street Address 2	
4 West 4th Ave	Suite 400	
City	State/Province/Country	ZIP/PostalCode
San Mateo	CALIFORNIA	94402
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Granadillo	Pedro	
Street Address 1	Street Address 2	
4 West 4th Ave	Suite 400	
City	State/Province/Country	ZIP/PostalCode
San Mateo	CALIFORNIA	94402
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Kash	Peter	M.
Street Address 1	Street Address 2	
4 West 4th Ave	Suite 400	
City	State/Province/Country	ZIP/PostalCode
San Mateo	CALIFORNIA	94402
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Litvack	Frank	Middle Name
Street Address 1	Street Address 2	
4 West 4th Ave	Suite 400	
City	State/Province/Country	ZIP/PostalCode
San Mateo	CALIFORNIA	94402
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Mieyal	Paul	A.
Street Address 1	Street Address 2	
4 West 4th Ave	Suite 400	
City	State/Province/Country	ZIP/PostalCode
San Mateo	CALIFORNIA	94402
Relationship: Executive Officer X Director		
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Schafer	Gregory	W.
Street Address 1	Street Address 2	
4 West 4th Ave	Suite 400	
City	State/Province/Country	ZIP/PostalCode

San Mateo	CALIFORNIA	94402
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):	_	
4. Industry Group		
Agriculture	Health Care	□ Pateiller
Banking & Financial Services	Biotechnology	☐ Retailing
Commercial Banking	Health Insurance	Restaurants
Insurance		Technology
Investing	Hospitals & Physicians	Computers
Investment Banking	X Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes No	Construction	
Other Banking & Financial Services	REITS & Finance	☐ Tourism & Travel Services
Business Services		Other Travel
Energy	Residential	Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net A	sset Value Range
No Revenues	_	Net Asset Value
\$1 - \$1,000,000	\[ \bigsize \] \\ \$1 - \\$5,000,00	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$	
\$5,000,001 - \$25,000,000	\$25,000,001 -	\$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 -	\$100,000,000
Over \$100,000,000	Over \$100,00	0,000
X Decline to Disclose	Decline to Dis	close
Not Applicable	Not Applicable	
6. Federal Exemption(s) and Exclusion(s) C	Laimed (select all that ann	(v)
		21
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505	
Rule 504 (b)(1)(i)	X Rule 506	
Rule 504 (b)(1)(ii)	봄	Act Section 4(5)
Rule 504 (b)(1)(iii)	Investment	Company Act Section 3(c)

Section	n 3(c)(1) Section 3(c)(9)	
☐ Section		
Section		
Section	1 3(c)(4) Section 3(c)(12)	
Section	1 3(c)(5) Section 3(c)(13)	
Section	n 3(c)(6) Section 3(c)(14)	
Section	n 3(c)(7)	
7. Type of Filing		
X New Notice Date of First Sale 2011-06-20 First Sale Yet to Occu.  Amendment	ır	
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	es X No	
9. Type(s) of Securities Offered (select all that apply)		
X Equity	Pooled Investment Fund Interests	
Debt	Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or Other Acquire Security	Right to Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combination or exchange offer?	transaction, such as a merger, acquisition Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number None	
Riverbank Capital Securities, Inc.	135310	
(Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD Number None	
Riverbank Capital Securities, Inc.	135310	
Street Address 1 689 5th Avenue	Street Address 2 Suite 12	
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10022
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
CALIFORNIA NEW JERSEY NEW YORK		
Recipient	Recipient CRD Number None	
Ladenburg Thalmann & Co., Inc.	505	
(Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD Number None	
Ladenburg Thalmann & Co., Inc. Street Address 1	505 Street Address 2	
520 Madison Avenue	9th Floor	
City	State/Province/Country	ZIP/Postal Code

NEW YORK

10022

New York

State(s) of Solicitation (select all that apply) Check "All States" or check individual States  All States  Foreign/non-US
NEW YORK
13. Offering and Sales Amounts
Total Offering Amount \$2,500,000 USD or ☐ Indefinite
Total Amount Sold \$2,500,000 USD
Total Remaining to be Sold \$0 USD or Indefinite
Clarification of Response (if Necessary):
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$175,000 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
Plus Warrants to purchase 250,000 shares
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$307,500 USD X Estimate
Clarification of Response (if Necessary):
Represents payments of salaries to Executive Officers
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2) (iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Nile Therapeutics, Inc.	/s/ Daron Evans	Daron Evans	Chief Financial Officer	2011-06-27

### currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.